190 related articles for article (PubMed ID: 30380075)
1. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
Yukimoto A; Hirooka M; Hiraoka A; Michitaka K; Ochi H; Joko K; Imai Y; Watanabe T; Koizumi Y; Yoshida O; Abe M; Hiasa Y
Jpn J Clin Oncol; 2019 Jan; 49(1):42-47. PubMed ID: 30380075
[TBL] [Abstract][Full Text] [Related]
2. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Maeda T; Yokoyama M; Wakamatsu T; Inoue M; Saito T; Kobayashi K; Kiyono S; Nakamura M; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N
Invest New Drugs; 2018 Apr; 36(2):332-339. PubMed ID: 28891038
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
[TBL] [Abstract][Full Text] [Related]
5. Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y; Yoo C; Lonardi S; Kim HD; Vivaldi C; Rimini M; Frassineti GL; Park SR; Rizzato MD; Ryu MH; Salani F; Rapposelli IG; Ryoo BY; Zagonel V; Massa V; Valgiusti M; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
Target Oncol; 2021 May; 16(3):401-410. PubMed ID: 33646487
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
7. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
8. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
10. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
Uchikawa S; Kawaoka T; Ando Y; Yamaoka K; Kosaka Y; Suehiro Y; Fujii Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Chayama K; Aikata H
Oncology; 2020; 98(10):727-733. PubMed ID: 32712613
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
13. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
16. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
[TBL] [Abstract][Full Text] [Related]
19. The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Fidan E; Fidan S; Merev E; Kazaz N
Niger J Clin Pract; 2022 Feb; 25(2):173-177. PubMed ID: 35170443
[TBL] [Abstract][Full Text] [Related]
20. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
